Life Sciences Insight

LumiraDx receives FDA Emergency Use Authorization (EUA) for COVID-19 Antigen Test

LumiraDx receives FDA Emergency Use Authorization (EUA) for COVID-19 Antigen Test

LumiraDx receives FDA Emergency Use Authorization for their COVID-19 Antigen Test. The Antigen test has demonstrated 97.6% accuracy vs PCR tests while providing a cost effective and time efficient solution. Taken from nasal swabs, the antigen test will detect nucleocapsid protein and provide results in under 12 minutes. Subsequently, this makes their antigen test one of the fastest and most sensitive antigen test on the market.

Source: https://www.lumiradx.com/us-en/news-events/lumiradx-receives-fda-uae-for-poc-covid-19-ag-test

SHARE
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn